1 / 10

Resverlogix Corp.

Resverlogix Corp. TSX: RVX. October 7th, 2009. About Company. Resverlogix based in Calgary-based TSX-list biotech company that is a world-leader in the development of an oral therapy to actually regress plaque build-ups in a person’s arteries.

cayla
Download Presentation

Resverlogix Corp.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Resverlogix Corp. TSX: RVX October 7th, 2009

  2. About Company Resverlogix based in Calgary-based TSX-list biotech company that is a world-leader in the development of an oral therapy to actually regress plaque build-ups in a person’s arteries. Plaque build-up also known as atherosclerosis, is the leading cause of cardiovascular disease (CVD), the leading killer of men and women in the industrialized world with over 18 million deaths reported in 2005 (World Health Organization).

  3. NexVas™ Plaque Regression (NexVas PR), is a novel technology platform with drugs that increase apolipoproteinA-I (ApoA-I) to reduce atherosclerosis (fatty plaque build-up in the arteries), which is the leading cause of CVD. ApoA-I is the key protective protein of high density lipoprotein (HDL), commonly known as the “good cholesterol”. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis. Resverlogix’s lead ApoA-I drug RVX-208 recently completed a Phase 1b/2a human clinical trial. About Company

  4. Donald J. McCaffrey President and CEO, Co-Founder Don is Resverlogix’s strategic leader, founder, mentor and the overall ‘heart’ of the company. Norman C.W. Wong, M.D., FRCP Chief Scientific Officer & Co-Founder Norman is the visionary for the scientific development of Resverlogix’s therapeutic platforms. Jan O. Johansson, M.D., Ph.D. Senior Vice President Medical Affairs Jan oversees the clinical and regulatory development, and provides scientific guidance to the corporation. Management

  5. Kenneth Lebioda, BA Senior VP Business & Corporate Development Ken is responsible for the business and market development of the company’s technology pipeline and alliance management. Gregory S. Wagner, Ph.D., DABT Senior VP Research & Development Greg oversees the company’s preclinical programs and provides extensive expertise in the areas of drug development, regulatory filings, and toxicology. Dr. F. Allan Gordon, M.D., Ph.D Senior Vice President of Clinical Development Allan will lead Resverlogix through clinical development. Management

  6. Share Structure & Financials Shares Outstanding: 39.4M Shares Fully Diluted: 49.6M Options/Warrants: 10.2M Current Price: $2.81 52 Week High/Low: $6.10/1.50 3 mo daily volume: 73,000 Cash on Hand: $7M

  7. 1-Year Stock Chart

  8. Calendar of Catalysts Sept: Announced successful 1b/2a human clinical trial Nov: Preparation of Stage 2 Human Clinical Trial by IVUS (intravascular ultrasound) Big Pharma could invest at any time

  9. Why Invest Now? Recent US analyst coverage by Rodman & Renshaw with 1-year $8 price target Moving towards a Stage 2 Human Clinical Trial (IVUS) Big Pharma could invest at any time as financing will need to be done prior to IVUS 1-per-cent and 5-per-cent regression of atherosclerosis would save the U.S. health care system between $22.9-billion (U.S.) and $76.8-billion (U.S.) annually

  10. TSX: RVX Contact Contact: Graeme A. Dick Website: www.resverlogix.com Phone: 403-561-8989 Email: graeme@briscocapital.com

More Related